The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Mitochondrial dysfunction in Alzheimer’s disease
Open accessAbstract
Alzheimer's disease (AD) is a chronic neurodegenerative disease characterized by progressive cognitive decline and distinct neuropathological features. The absence of a definitive cure presents a significant challenge in neurology and neuroscience. Early clinical manifestations, such as memory retrieval deficits and apathy, underscore the need for a deeper understanding of the disease's underlying mechanisms. While amyloid-β plaques and tau neurofibrillary tangles have dominated research efforts, accumulating evidence highlights mitochondrial dysfunction as a central factor in AD pathogenesis. Mitochondria, essential cellular organelles responsible for energy production necessary for neuronal function become impaired in AD, triggering several cellular consequences. Factors such as oxidative stress, disturbances in energy metabolism, failures in the mitochondrial quality control system, and dysregulation of calcium release are associated with mitochondrial dysfunction. These abnormalities are closely linked to the neurodegenerative processes driving AD development and progression. This review explores the intricate relationship between mitochondrial dysfunction and AD pathogenesis, emphasizing its role in disease onset and progression, while also considering its potential as a biomarker and a therapeutic target. Fig. 1: Graphic Abstract. Summary of main points discussed in the article. Created in https://BioRender.com • Dysfunctional mitochondria have been implicated in the pathogenesis of Alzheimer’s disease. • Mitochondrial homeostasis is necessary for cell energy production, calcium equilibrium and apoptotic signaling. • Mitochondria dysfunction leads to altered electron transport chain function, free radical generation and oxidative stress. • Mitochondria are emerging as biomarkers for early detection and monitoring of Alzheimer’s disease progression. • Therapeutic targeting of mitochondrial dysfunction offers a novel approach against Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 5×
“Moreover, dysregulation of sirtuins, particularly SIRT1 and SIRT3, can further un-dermine mitochondrial integrity by diminishing antioxidant defenses and disrupting ETC efficiency (Hou et al., 2019).”
InfluentialYoule, R. J., & Narendra, D. P. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3028 · Cited by 3,273
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy
Forman, H. J., & Zhang, H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00233-1 · Cited by 2,900 · cited 1×
“While mitochondrial-targeted antioxidants directly mitigate mitochondrial oxidative stress, a broader range of antioxidants, including natural compounds, can indirectly influence mitochondrial metabolism and alleviate AD-related pathophysiological processes (Forman and Zhang, 2021).”
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 2×
“The amyloid cascade theory suggests that AD pathology begins with the deposition of A β peptides in the brain, leading to the formation of amyloid plaques (Karran et al., 2011).”
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954 · cited 2×
“Metabolic dysregulation represents a fundamental pathological feature of AD, with mitochondrial dysfunction playing a central role in the bioenergetic failure, typical of the disease pathogenesis (Butterfield and Halliwell, 2019).”
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Alzheimer's Disease and the Amyloid-β Peptide
Murphy, M. P., & LeVine, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1221 · Cited by 1,750 · cited 1×
“A β plaques are aggregates of peptides derived from the sequential cleavage of the amyloid precursor protein (APP) by β - and γ -secretases, leading to cellular dysfunction and neurotoxicity in AD patients (Murphy and LeVine, 2010).”
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: Recent advances.
Wang, W., Zhao, F., Ma, X., Perry, G., & Zhu, X. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00376-6 · Cited by 1,274
Metadata
- Authors
- D’Alessandro, M. C. B., Kanaan, S., Geller, M., Praticò, D., & Daher, J. P. L.
- Venue
- Ageing Research Reviews
- Publisher
- Elsevier BV
- Published
- 2025-05
- Volume
- 107
- Pages
- 102713
- ISSN
- 1568-1637 (ISSN-L)
- OpenAlex
- W4408039530
- Cited by
- 192
- References
- 44
- FWCI
- 36.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mitochondrial dysfunction in Alzheimer’s disease. https://app.cochat.ai/papers/10.1016/j.arr.2025.102713
- The paper
- D’Alessandro, M. C. B., Kanaan, S., Geller, M., Praticò, D., & Daher, J. P. L. (2025). Mitochondrial dysfunction in Alzheimer’s disease. Ageing Research Reviews. https://doi.org/10.1016/j.arr.2025.102713
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.